These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported Terminated||2007-003976-20||A randomised, double blind, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single dose of GRC 6211, a TRPV1 receptor antagonist on pain following third mo...||2008-02-25||due-trials|
|Reported results||2011-000107-40||A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumatoid ...||2012-12-20||due-trials|
|Reported results||2011-000270-57||A phase II, 12-week randomized, double-blind, triple dummy, parallel group, placebo-controlled, dose range finding study to evaluate safety, tolerability and efficacy of revamilast in patients with c...||2013-04-08||due-trials|
|Ongoing, reported early||2011-003147-22||A Multicenter, Open-Label, Comparator-Controlled, Parallel Group, Phase 3 Study to Assess the Efficacy and Safety of Clotrimazole/Clindamycin (200 mg/100 mg FDC) Ovules Compared with Metronidazole (50...||not-yet-due|
|Not reported||2011-005879-16||A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Neur...||2012-06-18||due-trials|
|Reported results||2012-002320-33||A Phase 2, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Perip...||2014-07-23||due-trials|
|Exempt, with results||2012-002567-99||An integrated Phase I/IIa study to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled GRC 17536 in healthy adult volunteers and multiple ascending doses in pat...||2013-10-15||not-yet-due|
|Reported results||2013-002728-17||A Phase 2a, Multi-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Inhaled GRC 17536, Administered for 4 Weeks, in Patients w...||2014-07-30||due-trials|